Genome Editing Market Share

North America Market Insights

North America is considered the dominating region in the genome editing industry, with an anticipated market share of 42.6% by the end of 2034, along with a 16.8% growth rate. The U.S. is readily driving the market exposure in the region through federal investments and Medicare spending on CRISPR therapies. Additionally, FDA acceptances, especially of gene-editing treatments as of 2022, is also another factor for the market’s growth in the region. Besides, Canada has significantly contributed through its Health Canada initiatives, all of which are responsible for positively impacting the market development in the overall region.

The genome editing sector in the U.S. is significantly increasing, with an expected revenue share of 39.2% during the forecast duration, highly attributed to the NIH’s USD 4.9 billion yearly R&D funding, as well as the FDA’s fast-track approval, including acceptance of 6 new CRISPR as of 2022. In addition, Medicare’s USD 850 million spending as of 2024 has enhanced CAR-T and sickle cell therapies coverage. Meanwhile, regional organizations, such as Thermo Fisher’s USD 1.7 billion viral vector production, have aimed to reduce import dependency, thus suitable for market growth.

The market in Canada is also gaining increased importance with a growth rate of 13.5%, effectively driven by Ontario’s 22% hike in funding for chronic disorders and federal funding of USD 3.3 billion for healthcare services. Besides, Health Canada has accepted 4 CRISPR therapies as of 2024 by duplicating the EU and the U.S. reforms. Meanwhile, the aspect of private and public collaborations has successfully bolstered localized manufacturing processes. In this regard, BioteCanada’s USD 550 million fund has been effective for uplifting the overall market in the country.

North America Market: Trade & Supply Chain Facilities (2021-2025)

APAC Market Insights

Asia Pacific in the genome editing market is considered the fastest-growing region, with an expected market share of 22.2% during the forecast duration. The market’s growth in the region is fueled by China’s dominance, which is 48.5% of the region’s share for CRISPR. In addition, the country is leading in increased patient volume, which is highly supported by the NMPA’s fast-tracked acceptance of gene therapies. Meanwhile, India is also fueling the market growth through generic collaborations and a surge in government spending. Besides, South Korea’s 20230 Bio-Vision has allocated USD 2.3 billion for gene editing, thereby denoting a growth opportunity for the market.

The genome editing industry in China is gaining increased traction, which is driven by speedy administrative approvals as well as robust state funding. For instance, the regional government has initiated the allocation of USD 5.5 billion for CRISPR commercialization and research as of 2024, and the NMPA has readily fast-tracked 4 gene therapies as of 2023, which includes the world’s first-ever CRISPR-based cancer treatment solutions. Besides, with over 2.7 million patients suitable for undergoing gene therapies, the country is leading in agricultural applications, thus creating a positive impact on the market.

The market in India is projected to achieve at least 17% of the region’s revenue by 2034, highly attributed to administrative support and cost-effective advancements. Besides, the 2024 National Biotech Strategy has provided an allocation of USD 2.4 billion for conducting CRISPR research, while collaborations, such as Intellia Therapeutics’ generic CRISPR deals, have successfully reduced therapy expenses by approximately 44%. Meanwhile, with over 2.6 million patients demanding gene therapies, the country has deliberately focused on thalassemia and sickle cell anemia, thus denoting a huge market growth opportunity.

Europe Market Insights

Europe in the genome editing market is expected to account for a considerable share of 28.1% by the end of the forecast timeline. The market’s exposure in the region is effectively attributed to government-based funding as well as the presence of a robust regulatory framework. Besides, the EU has already allocated € 2.7 billion through HERA, particularly for CRISPR-powered therapies, while the UK and Germany are deliberately leading in the implementation. The EU Medicines Agency (EMA) has rapidly fast-tracked 14 gene therapies since 2022, which includes CRISPR treatment facilities for sickle cell disorder, thus suitable for enhancing the market exposure.

The genome editing sector in Germany is dominating with a projected revenue share of 37.5% by the end of the forecast duration, which is highly driven by €4.8 billion in yearly government spending. The Federal Joint Committee (G-BA) has extended reimbursement for CRISPR-based therapies since 2024, which covers almost 85% of suitable patients. Meanwhile, BioNTech’s mRNA-CRISPR hybrid entered Phase III clinical trials by targeting €2.4 billion in oncology revenue. Therefore, all these factors are suitable enough to uplift the market in the country.

The market in the UK is also gaining increased traction, and is further anticipated to account for 26.5% of the region’s share during the forecast timeline, readily administered by the NHS’s 8.5% budget allocation. Vertex’s Casgevy emerged as the first-ever NHS-backed CRISPR therapy as of 2023, leading to treat more than 520 sickle cell patients. Besides, the Cell and Gene Therapy Catapult initiated an investment of £ 1.1 billion in manufacturing, thereby diminishing production expenses by approximately 35%, which further denotes an optimistic outlook for the overall market growth.

Europe Market: Government Investments & Policies (2021–2025)